View by Specialty

Trending

DERM1124DesaiQAGraphic01
November 11, 2024
6 min read
Save

Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access

Liver/Biliary Disorders News

SPONSORED CONTENT
Save
SPONSORED CONTENT
August 15, 2024
2 min read
Save

Noninvasive model minimizes the risk for missing high-risk varices in unresectable HCC

Noninvasive model minimizes the risk for missing high-risk varices in unresectable HCC

A model using both clinical and imaging data predicted the absence of high-risk varices in patients with unresectable hepatocellular carcinoma and may help avoid unnecessary upper endoscopy in low-risk patients, research showed.

SPONSORED CONTENT
August 14, 2024
2 min read
Save

FDA approves Gilead’s Livdelzi for treatment of primary biliary cholangitis

FDA approves Gilead’s Livdelzi for treatment of primary biliary cholangitis

Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.

Trending

DERM1124DesaiQAGraphic01
November 11, 2024
6 min read
Save

Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access

SPONSORED CONTENT
August 14, 2024
2 min read
Save

HCV elimination efforts in Georgia lower infections by 61%, may advance reaching 2030 goal

HCV elimination efforts in Georgia lower infections by 61%, may advance reaching 2030 goal

A hepatitis C elimination program in Georgia reduced the estimated annual incidence of new infections by 61% since its launch in April 2015, which may accelerate efforts to reach the global 2030 elimination goal.

SPONSORED CONTENT
August 09, 2024
5 min read
Save

Q&A: MASH experts emphasize using noninvasive tests to assess response to Rezdiffra

Q&A: MASH experts emphasize using noninvasive tests to assess response to Rezdiffra

With the FDA label for Rezdiffra excluding the need for liver biopsy, experts proposed recommendations to “fill the gap” on how to leverage noninvasive tests to assess treatment response in metabolic dysfunction-associated steatohepatitis.

SPONSORED CONTENT
August 08, 2024
2 min read
Save

Nearly 15.6 million Americans using botanical supplements may be at risk for liver injury

Nearly 15.6 million Americans using botanical supplements may be at risk for liver injury

Researchers estimated that nearly 15.6 million Americans consumed at least one potentially hepatotoxic botanical product in the past 30 days, similar to usage reports for simvastatin and NSAIDS.

SPONSORED CONTENT
August 07, 2024
1 min read
Save

Liver transplant bests chemotherapies for improved survival in colorectal liver metastasis

Liver transplant bests chemotherapies for improved survival in colorectal liver metastasis

Patients who underwent liver transplantation vs. alternative therapy for unresectable colorectal liver metastasis had higher progression-free and overall survival, as well as lower rates of recurrence, researchers reported in JAMA Surgery.

SPONSORED CONTENT
August 06, 2024
3 min read
Save

Pemvidutide linked to ‘rapid and potent’ reduction in liver fat in MASLD at 12 weeks

Pemvidutide linked to ‘rapid and potent’ reduction in liver fat in MASLD at 12 weeks

Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.

SPONSORED CONTENT
July 31, 2024
2 min read
Save

Model may ‘serve as a starting point’ to identify patients with MASLD at high risk for HCC

Model may ‘serve as a starting point’ to identify patients with MASLD at high risk for HCC

A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.

SPONSORED CONTENT
July 30, 2024
2 min read
Save

Prevalence of cirrhosis ‘more than double’ in transgender vs. cisgender adults

Prevalence of cirrhosis ‘more than double’ in transgender vs. cisgender adults

Transgender adults had “more than double” the prevalence of cirrhosis vs. cisgender adults, as well as higher rates of comorbidities linked to liver disease progression, researchers reported in The American Journal of Gastroenterology.

SPONSORED CONTENT
July 26, 2024
2 min read
Save

Up to 13% with dementia may instead have ‘treatable’ HE due to undiagnosed cirrhosis

Up to 13% with dementia may instead have ‘treatable’ HE due to undiagnosed cirrhosis

Up to 13% of patients with dementia have lab values that suggest undiagnosed cirrhosis and possible hepatic encephalopathy, an “easily treatable” cause of cognitive impairment, according to a study in The American Journal of Medicine.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails